Innoviva, Inc. (INVA)
USD 17.5
(-3.21%)
USD 17.5
(-3.21%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.24 Billion USD | 0.98% |
| 2022 | 1.23 Billion USD | 32.93% |
| 2021 | 926.39 Million USD | -7.32% |
| 2020 | 999.57 Million USD | 37.9% |
| 2019 | 724.82 Million USD | 32.22% |
| 2018 | 548.19 Million USD | 49.23% |
| 2017 | 367.33 Million USD | -3.08% |
| 2016 | 378.99 Million USD | -10.63% |
| 2015 | 424.07 Million USD | -18.71% |
| 2014 | 521.65 Million USD | -23.43% |
| 2013 | 681.25 Million USD | 84.83% |
| 2012 | 368.58 Million USD | 42.43% |
| 2011 | 258.78 Million USD | -21.87% |
| 2010 | 331.2 Million USD | 82.59% |
| 2009 | 181.39 Million USD | -23.19% |
| 2008 | 236.15 Million USD | 45.79% |
| 2007 | 161.98 Million USD | -38.27% |
| 2006 | 262.42 Million USD | 16.72% |
| 2005 | 224.83 Million USD | -21.39% |
| 2004 | 286.02 Million USD | 128.0% |
| 2003 | 125.44 Million USD | -34.9% |
| 2002 | 192.71 Million USD | 0.0% |
| 2000 | 246.85 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.22 Billion USD | -3.37% |
| 2024 Q1 | 1.26 Billion USD | 1.94% |
| 2023 Q1 | 1.12 Billion USD | -8.26% |
| 2023 FY | 1.24 Billion USD | 0.98% |
| 2023 Q2 | 1.11 Billion USD | -1.02% |
| 2023 Q3 | 1.18 Billion USD | 6.25% |
| 2023 Q4 | 1.24 Billion USD | 4.66% |
| 2022 Q3 | 1.32 Billion USD | 16.71% |
| 2022 Q2 | 1.13 Billion USD | 2.72% |
| 2022 Q4 | 1.23 Billion USD | -7.25% |
| 2022 Q1 | 1.1 Billion USD | 19.55% |
| 2022 FY | 1.23 Billion USD | 32.93% |
| 2021 FY | 926.39 Million USD | -7.32% |
| 2021 Q1 | 1.08 Billion USD | 8.88% |
| 2021 Q2 | 789.15 Million USD | -27.49% |
| 2021 Q3 | 887.23 Million USD | 12.43% |
| 2021 Q4 | 926.39 Million USD | 4.41% |
| 2020 Q4 | 999.57 Million USD | 8.38% |
| 2020 Q3 | 922.25 Million USD | 4.85% |
| 2020 Q2 | 879.61 Million USD | 11.63% |
| 2020 Q1 | 788.01 Million USD | 8.72% |
| 2020 FY | 999.57 Million USD | 37.9% |
| 2019 Q1 | 590.11 Million USD | 7.65% |
| 2019 FY | 724.82 Million USD | 32.22% |
| 2019 Q2 | 642.3 Million USD | 8.84% |
| 2019 Q3 | 675.95 Million USD | 5.24% |
| 2019 Q4 | 724.82 Million USD | 7.23% |
| 2018 FY | 548.19 Million USD | 49.23% |
| 2018 Q4 | 548.19 Million USD | 97.41% |
| 2018 Q1 | 276.74 Million USD | -24.66% |
| 2018 Q2 | 338.69 Million USD | 22.38% |
| 2018 Q3 | 277.69 Million USD | -18.01% |
| 2017 Q3 | 390.97 Million USD | 5.09% |
| 2017 Q1 | 391.87 Million USD | 3.4% |
| 2017 FY | 367.33 Million USD | -3.08% |
| 2017 Q4 | 367.33 Million USD | -6.05% |
| 2017 Q2 | 372.02 Million USD | -5.07% |
| 2016 Q2 | 378.1 Million USD | -2.51% |
| 2016 FY | 378.99 Million USD | -10.63% |
| 2016 Q4 | 378.99 Million USD | 2.28% |
| 2016 Q3 | 370.54 Million USD | -2.0% |
| 2016 Q1 | 387.82 Million USD | -8.55% |
| 2015 FY | 424.07 Million USD | -18.71% |
| 2015 Q4 | 424.07 Million USD | -3.1% |
| 2015 Q3 | 437.63 Million USD | -5.29% |
| 2015 Q2 | 462.08 Million USD | -5.45% |
| 2015 Q1 | 488.69 Million USD | -6.32% |
| 2014 Q3 | 553.71 Million USD | -8.57% |
| 2014 FY | 521.65 Million USD | -23.43% |
| 2014 Q4 | 521.65 Million USD | -5.79% |
| 2014 Q1 | 605.03 Million USD | -11.19% |
| 2014 Q2 | 605.61 Million USD | 0.1% |
| 2013 Q4 | 681.25 Million USD | 2.29% |
| 2013 Q2 | 594.7 Million USD | 0.54% |
| 2013 Q1 | 591.51 Million USD | 60.49% |
| 2013 Q3 | 666.01 Million USD | 11.99% |
| 2013 FY | 681.25 Million USD | 84.83% |
| 2012 FY | 368.58 Million USD | 42.43% |
| 2012 Q1 | 217.72 Million USD | -15.86% |
| 2012 Q4 | 368.58 Million USD | -4.0% |
| 2012 Q2 | 399.42 Million USD | 83.45% |
| 2012 Q3 | 383.94 Million USD | -3.88% |
| 2011 Q3 | 283.32 Million USD | -6.53% |
| 2011 FY | 258.78 Million USD | -21.87% |
| 2011 Q1 | 315.1 Million USD | -4.86% |
| 2011 Q2 | 303.12 Million USD | -3.8% |
| 2011 Q4 | 258.78 Million USD | -8.66% |
| 2010 Q4 | 331.2 Million USD | 55.8% |
| 2010 FY | 331.2 Million USD | 82.59% |
| 2010 Q3 | 212.58 Million USD | -8.55% |
| 2010 Q2 | 232.44 Million USD | -6.99% |
| 2010 Q1 | 249.93 Million USD | 37.78% |
| 2009 Q4 | 181.39 Million USD | -1.13% |
| 2009 FY | 181.39 Million USD | -23.19% |
| 2009 Q1 | 214.79 Million USD | -9.05% |
| 2009 Q2 | 206.08 Million USD | -4.05% |
| 2009 Q3 | 183.47 Million USD | -10.97% |
| 2008 Q3 | 255.26 Million USD | -9.29% |
| 2008 FY | 236.15 Million USD | 45.79% |
| 2008 Q1 | 299.51 Million USD | 84.91% |
| 2008 Q4 | 236.15 Million USD | -7.48% |
| 2008 Q2 | 281.39 Million USD | -6.05% |
| 2007 Q1 | 247.65 Million USD | -5.63% |
| 2007 FY | 161.98 Million USD | -38.27% |
| 2007 Q4 | 161.98 Million USD | -18.45% |
| 2007 Q3 | 198.62 Million USD | -4.51% |
| 2007 Q2 | 208 Million USD | -16.01% |
| 2006 FY | 262.42 Million USD | 16.72% |
| 2006 Q4 | 262.42 Million USD | -10.24% |
| 2006 Q3 | 292.35 Million USD | -8.32% |
| 2006 Q2 | 318.89 Million USD | -2.58% |
| 2006 Q1 | 327.33 Million USD | 45.59% |
| 2005 Q4 | 224.83 Million USD | 14.14% |
| 2005 Q2 | 233.8 Million USD | -9.8% |
| 2005 FY | 224.83 Million USD | -21.39% |
| 2005 Q3 | 196.98 Million USD | -15.75% |
| 2005 Q1 | 259.19 Million USD | -9.38% |
| 2004 Q4 | 286.02 Million USD | 39.54% |
| 2004 Q2 | 219 Million USD | 0.0% |
| 2004 Q3 | 204.97 Million USD | -6.4% |
| 2004 FY | 286.02 Million USD | 128.0% |
| 2003 FY | 125.44 Million USD | -34.9% |
| 2002 FY | 192.71 Million USD | 0.0% |
| 2000 FY | 246.85 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 16.436% |
| Alkermes plc | 2.13 Billion USD | 41.789% |
| Agenus Inc. | 313.91 Million USD | -296.131% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 67.531% |
| Aptorum Group Limited | 20.64 Million USD | -5924.717% |
| Ardelyx, Inc. | 297.57 Million USD | -317.875% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -62.433% |
| Bicycle Therapeutics plc | 595.34 Million USD | -108.872% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -1587.209% |
| ChromaDex Corporation | 54.96 Million USD | -2162.403% |
| Chimerix, Inc. | 212.77 Million USD | -484.426% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -4298.308% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -181.995% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 44.227% |
| Precision BioSciences, Inc. | 159.78 Million USD | -678.257% |
| Dyadic International, Inc. | 8.21 Million USD | -15029.229% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -3817.791% |
| Fortress Biotech, Inc. | 167.52 Million USD | -642.277% |
| Lantern Pharma Inc. | 43.64 Million USD | -2748.969% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -670.751% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -8471.981% |
| Incyte Corporation | 6.78 Billion USD | 81.665% |
| IO Biotech, Inc. | 150.71 Million USD | -725.055% |
| Jaguar Health, Inc. | 50.76 Million USD | -2349.633% |
| Novavax, Inc. | 1.85 Billion USD | 32.977% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -226.889% |
| Opthea Limited | 188.79 Million USD | -558.668% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -49.269% |
| ContextLogic Inc. | 423 Million USD | -193.973% |
| MiMedx Group, Inc. | 239.04 Million USD | -420.194% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -615.786% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -23953.751% |
| NextCure, Inc. | 129.41 Million USD | -860.845% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -2205.01% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -3285.627% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -3749.748% |
| Vaxcyte, Inc. | 1.4 Billion USD | 11.678% |
| PDS Biotechnology Corporation | 59.39 Million USD | -1993.796% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -94.132% |
| Pharming Group N.V. | 462.85 Million USD | -168.661% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -3114.858% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -97.836% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -6471.171% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -6471.171% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -652.182% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -2645.837% |
| Acelyrin, Inc. | 742.69 Million USD | -67.433% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -18779.567% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -19320.693% |
| Summit Therapeutics Inc. | 202.94 Million USD | -512.719% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -1571.965% |
| Senti Biosciences, Inc. | 119.48 Million USD | -940.731% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -444.581% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -639.417% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -14949.098% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -25948.752% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -165.032% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -905.642% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -352.268% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -162.987% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -12205.858% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -479.707% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -109735.014% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -200.479% |
| Immix Biopharma, Inc. | 19.92 Million USD | -6140.888% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -236.06% |
| MEI Pharma, Inc. | 41.37 Million USD | -2905.455% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -3737.274% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -264.881% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -960.787% |
| Fortress Biotech, Inc. | 167.52 Million USD | -642.277% |
| Precigen, Inc. | 151.04 Million USD | -723.28% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -3555.438% |
| AlloVir, Inc. | 190.79 Million USD | -551.747% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -230.324% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -145.647% |
| ImmuCell Corporation | 43.8 Million USD | -2738.532% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -91.51% |
| Onconetix, Inc. | 88.82 Million USD | -1300.008% |
| PureTech Health plc | 693.97 Million USD | -79.187% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -1172.976% |
| Elevation Oncology, Inc. | 89.09 Million USD | -1295.772% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -19950.097% |
| Seer, Inc. | 436.26 Million USD | -185.032% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -1423.962% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -839.042% |
| ESSA Pharma Inc. | 149.12 Million USD | -733.885% |
| GlycoMimetics, Inc. | 45.31 Million USD | -2644.051% |
| GT Biopharma, Inc. | 14.1 Million USD | -8713.573% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -303.876% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -414.477% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -163.507% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -2352.822% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -1206.04% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -196785.786% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -119.569% |
| Aptose Biosciences Inc. | 12.92 Million USD | -9522.772% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -5523.094% |
| Soligenix, Inc. | 9.79 Million USD | -12592.31% |
| Century Therapeutics, Inc. | 360.69 Million USD | -244.757% |
| Kura Oncology, Inc. | 448.93 Million USD | -176.99% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -356.921% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -7089.98% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -1021.172% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -506.142% |
| Autolus Therapeutics plc | 375.38 Million USD | -231.265% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -394.169% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -250.102% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -2430.951% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -88.087% |
| GRI Bio, Inc. | 2.95 Million USD | -41967.219% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -11625.417% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -629.265% |
| IGM Biosciences, Inc. | 423.41 Million USD | -193.688% |
| INmune Bio, Inc. | 57 Million USD | -2081.553% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -458.864% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -1381.402% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -4661.319% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -17965.84% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -1553.028% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -744.441% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -651.346% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -97.506% |
| Verastem, Inc. | 149.71 Million USD | -730.566% |
| Abeona Therapeutics Inc. | 64 Million USD | -1842.919% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -142.799% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -705.083% |
| Histogen Inc. | 19.07 Million USD | -6419.724% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -5390.055% |
| Surrozen, Inc. | 46.08 Million USD | -2598.583% |
| Organovo Holdings, Inc. | 6.34 Million USD | -19485.872% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -28760.911% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -763.386% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -10436.409% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -1552.106% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -14496.437% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -242.593% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -6772.332% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -189.59% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -9759.932% |
| Apollomics, Inc. | 55.38 Million USD | -2145.124% |
| Amarin Corporation plc | 831.68 Million USD | -49.517% |
| Mesoblast Limited | 669.15 Million USD | -85.833% |
| Turnstone Biologics Corp. | 112.81 Million USD | -1002.253% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -115.977% |
| Synaptogenix, Inc. | 31.11 Million USD | -3896.658% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -10106.065% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -126.892% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -21075.949% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -16829.613% |
| Exelixis, Inc. | 2.94 Billion USD | 57.738% |
| Better Therapeutics, Inc. | 22.94 Million USD | -5319.984% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -241.118% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -57.659% |
| NLS Pharmaceutics AG | 1.84 Million USD | -67238.86% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -15485.462% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -8362.11% |
| Gritstone bio, Inc. | 177.76 Million USD | -599.507% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -1203.74% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -6861.64% |
| Avid Bioservices, Inc. | 336.55 Million USD | -269.479% |
| Insmed Incorporated | 1.32 Billion USD | 6.492% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -12815.065% |
| MediWound Ltd. | 66.45 Million USD | -1771.089% |
| OmniAb, Inc. | 401.98 Million USD | -209.342% |
| Alector, Inc. | 621.82 Million USD | -99.976% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -246.767% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -23022.109% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -2093.444% |
| Zai Lab Limited | 1.03 Billion USD | -19.995% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -159.901% |
| Aura Biosciences, Inc. | 255.07 Million USD | -387.506% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -65.795% |
| Immunic, Inc. | 54.29 Million USD | -2190.11% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -367.09% |
| Veracyte, Inc. | 1.13 Billion USD | -9.288% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -10417.888% |
| FibroGen, Inc. | 423.52 Million USD | -193.606% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -35297.296% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -26153.129% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -22802.883% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 89.086% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -14022.737% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -140.313% |
| TG Therapeutics, Inc. | 329.58 Million USD | -277.292% |
| Galecto, Inc. | 38.22 Million USD | -3152.955% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -4236.403% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 71.461% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -428.244% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -4905.664% |
| XBiotech Inc. | 227.24 Million USD | -447.215% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -1203.74% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -772.025% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -334.92% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -872.485% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -225.526% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 16.6% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -240.834% |
| Vaxxinity, Inc. | 44.35 Million USD | -2703.659% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -140.542% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -6582.169% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -307.64% |
| NexImmune, Inc. | 8.59 Million USD | -14369.565% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -11505.086% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -7160.341% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 96.241% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -5513.74% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -316906.87% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -617.426% |
| Ainos, Inc. | 31.84 Million USD | -3805.266% |
| Pluri Inc. | 39.52 Million USD | -3045.969% |
| Prothena Corporation plc | 696.38 Million USD | -78.567% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -339.999% |
| Celularity Inc. | 143.88 Million USD | -764.213% |
| Rallybio Corporation | 115.62 Million USD | -975.512% |
| Cue Biopharma, Inc. | 61.53 Million USD | -1920.977% |
| MeiraGTx Holdings plc | 458.16 Million USD | -171.409% |
| Omeros Corporation | 378.26 Million USD | -228.736% |
| Humacyte, Inc. | 128.22 Million USD | -869.8% |
| Immunocore Holdings plc | 597 Million USD | -108.292% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -3878.077% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -1714.544% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -18.514% |
| CalciMedica, Inc. | 12.18 Million USD | -10105.228% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -390.245% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -627.589% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -299.796% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -119.973% |
| Pulmatrix, Inc. | 33.95 Million USD | -3561.897% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -4480.811% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -782.809% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 4.417% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -855.155% |
| Cytokinetics, Incorporated | 824.31 Million USD | -50.853% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -5786.981% |
| Nutriband Inc. | 7.51 Million USD | -16442.258% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -1474.977% |
| Vor Biopharma Inc. | 209.82 Million USD | -492.632% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 82.783% |
| Evogene Ltd. | 51.1 Million USD | -2333.43% |
| ProKidney Corp. | 420.55 Million USD | -195.684% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -2167.808% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -12961.667% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -127.59% |
| CorMedix Inc. | 82.05 Million USD | -1415.364% |
| BioLineRx Ltd. | 63.92 Million USD | -1845.259% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -208.894% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -4309.599% |
| Atai Life Sciences N.V. | 293.47 Million USD | -323.714% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -662.282% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -875.927% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -121.254% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -1185.691% |
| MediciNova, Inc. | 66.26 Million USD | -1776.426% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -1313.912% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -27766.546% |
| GeoVax Labs, Inc. | 9.28 Million USD | -13295.213% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -111.396% |
| Biomea Fusion, Inc. | 199.92 Million USD | -521.981% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 34.662% |
| Mereo BioPharma Group plc | 66.49 Million USD | -1769.963% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -156.342% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -102.896% |
| Absci Corporation | 234.48 Million USD | -430.325% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -16899.412% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -265.855% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -653.266% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -136.264% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -347.799% |
| Allakos Inc. | 243.61 Million USD | -410.45% |
| Imunon, Inc. | 21.91 Million USD | -5573.433% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -382.552% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -100.076% |
| BioAtla, Inc. | 119.65 Million USD | -939.218% |
| NLS Pharmaceutics AG | 1.84 Million USD | -67238.86% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -38518.23% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -93.44% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -1196.197% |
| XOMA Corporation | 234.3 Million USD | -430.731% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -462.075% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -888.134% |
| aTyr Pharma, Inc. | 122.06 Million USD | -918.709% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -707.981% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -114.298% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -153.558% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -1025.661% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -8103.874% |
| Akari Therapeutics, Plc | 4.35 Million USD | -28453.548% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -7198.719% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 28.257% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -40221.422% |
| UroGen Pharma Ltd. | 178.31 Million USD | -597.381% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -164.162% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -223667.039% |
| Orgenesis Inc. | 14.55 Million USD | -8445.265% |
| Entera Bio Ltd. | 11.76 Million USD | -10469.545% |
| GH Research PLC | 226.3 Million USD | -449.495% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -2173.571% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -1057.44% |
| Xencor, Inc. | 952.69 Million USD | -30.526% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -15875.637% |
| Replimune Group, Inc. | 487.72 Million USD | -154.962% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -15306.93% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -91.769% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -40221.422% |
| Portage Biotech Inc. | 7.77 Million USD | -15885.435% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -27766.546% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -349.009% |
| OncoCyte Corporation | 74.89 Million USD | -1560.4% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -61058.649% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -21389.264% |
| Purple Biotech Ltd. | 44.3 Million USD | -2706.887% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -3543.87% |
| scPharmaceuticals Inc. | 94.47 Million USD | -1216.173% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -6791.16% |
| HilleVax, Inc. | 344.43 Million USD | -261.029% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -39053.243% |
| Tharimmune, Inc. | 10.94 Million USD | -11259.97% |
| Genprex, Inc. | 10.67 Million USD | -11553.59% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -150.609% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -1191.928% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -51157.502% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -29752.95% |
| OKYO Pharma Limited | 1.54 Million USD | -80580.987% |
| Savara Inc. | 177.56 Million USD | -600.315% |
| Curis, Inc. | 77.28 Million USD | -1509.051% |
| Daré Bioscience, Inc. | 21.28 Million USD | -5742.94% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -1844.535% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -15278.518% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -6319.426% |
| BeiGene, Ltd. | 5.8 Billion USD | 78.58% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -10118.646% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 40.462% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -247.396% |
| Erasca, Inc. | 395.29 Million USD | -214.575% |
| bluebird bio, Inc. | 619.16 Million USD | -100.837% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -28662.454% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 81.824% |
| DBV Technologies S.A. | 182.98 Million USD | -579.564% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -28662.454% |
| Moderna, Inc. | 18.42 Billion USD | 93.251% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -6726.08% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -10632.841% |
| Molecular Templates, Inc. | 35.38 Million USD | -3414.419% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -799.365% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -57.623% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -309.378% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -1096.301% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -167.061% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -296.733% |
| MacroGenics, Inc. | 306.82 Million USD | -305.289% |
| RenovoRx, Inc. | 1.46 Million USD | -84723.124% |
| Adicet Bio, Inc. | 207.29 Million USD | -499.873% |
| Prime Medicine, Inc. | 193.85 Million USD | -541.476% |
| Aditxt, Inc. | 44.57 Million USD | -2689.488% |
| Adagene Inc. | 115.72 Million USD | -974.501% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -27817.697% |
| Quantum-Si incorporated | 298.25 Million USD | -316.934% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 16.4% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -16030.33% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -253.992% |
| SciSparc Ltd. | 11.18 Million USD | -11020.613% |
| Vericel Corporation | 353.65 Million USD | -251.614% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -10082.157% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -2085.402% |
| Generation Bio Co. | 374.75 Million USD | -231.816% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -388.289% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -684.216% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -264.275% |
| Invivyd, Inc. | 229.18 Million USD | -442.587% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -47.338% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -10118.393% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -581.785% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -5988.46% |
| 2seventy bio, Inc. | 565.42 Million USD | -119.924% |
| ADMA Biologics, Inc. | 329.18 Million USD | -277.757% |
| Clene Inc. | 52.34 Million USD | -2275.78% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -2017.172% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -857.324% |
| GeoVax Labs, Inc. | 9.28 Million USD | -13295.213% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -90.226% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -1100.167% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -853.712% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -1174.711% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -1651.492% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -412.674% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 36.559% |
| Evaxion Biotech A/S | 12.88 Million USD | -9548.101% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -393.338% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -65.209% |
| Trevena, Inc. | 40.6 Million USD | -2962.448% |
| Surrozen, Inc. | 46.08 Million USD | -2598.583% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -450.573% |
| Cingulate Inc. | 3.49 Million USD | -35515.918% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -7377.942% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1792.993% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -10542.248% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -363.102% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -66.032% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -887.757% |
| Clearmind Medicine Inc. | 4.32 Million USD | -28655.669% |
| Kronos Bio, Inc. | 213.27 Million USD | -483.042% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -678.243% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -14425.916% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -237.46% |
| Statera Biopharma, Inc. | 21.16 Million USD | -5773.999% |
| ImmunityBio, Inc. | 504.45 Million USD | -146.507% |
| Korro Bio, Inc. | 221.66 Million USD | -460.99% |
| Kineta, Inc. | 10.28 Million USD | -11995.195% |
| BioVie Inc. | 25.2 Million USD | -4832.918% |
| Codexis, Inc. | 136.56 Million USD | -810.587% |
| Celularity Inc. | 143.88 Million USD | -764.213% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -95.719% |
| Celcuity Inc. | 191.21 Million USD | -550.304% |
| Virax Biolabs Group Limited | 5.48 Million USD | -22575.311% |
| Cibus, Inc. | 544.41 Million USD | -128.413% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -887.741% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -5952.896% |
| IN8bio, Inc. | 33.7 Million USD | -3588.947% |
| Kodiak Sciences Inc. | 479.37 Million USD | -159.403% |
| Annexon, Inc. | 297.67 Million USD | -317.741% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -618.749% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -804.573% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -5823.436% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 58.412% |
| Eyenovia, Inc. | 28.77 Million USD | -4220.827% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -439.417% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -17113.552% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -1941.012% |
| Arcellx, Inc. | 825.13 Million USD | -50.704% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -1423.215% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -168.997% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -3943.925% |
| Moolec Science SA | 24.05 Million USD | -5070.23% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -300.97% |
| Geron Corporation | 394.07 Million USD | -215.55% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -1122.601% |
| Royalty Pharma plc | 16.38 Billion USD | 92.409% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -109.004% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -17677.554% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -10239.023% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -450.078% |
| Humacyte, Inc. | 128.22 Million USD | -869.8% |
| Structure Therapeutics Inc. | 482.01 Million USD | -157.98% |
| 89bio, Inc. | 596.26 Million USD | -108.548% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -393.158% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -67116.595% |
| Genelux Corporation | 27.89 Million USD | -4358.133% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -1290.901% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -442.001% |
| Notable Labs, Ltd. | 19.54 Million USD | -6263.579% |
| Liquidia Corporation | 120.43 Million USD | -932.547% |
| Mustang Bio, Inc. | 17.74 Million USD | -6908.832% |
| Immunovant, Inc. | 666.71 Million USD | -86.513% |
| Quantum-Si incorporated | 298.25 Million USD | -316.934% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -761.148% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -2195.988% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -608.365% |
| Acasti Pharma Inc. | 73.3 Million USD | -1596.462% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -27216.13% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -4661.319% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -28.888% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -23860.051% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -5358.527% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -2309.757% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -588.195% |
| PepGen Inc. | 143.05 Million USD | -769.269% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -3153.806% |
| United Therapeutics Corporation | 7.16 Billion USD | 82.65% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -6381.663% |
| Solid Biosciences Inc. | 164.93 Million USD | -653.919% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -21075.949% |
| Immuneering Corporation | 102.58 Million USD | -1112.178% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -28760.911% |
| Silo Pharma, Inc. | 7.74 Million USD | -15953.245% |
| Belite Bio, Inc | 94.64 Million USD | -1213.906% |
| XOMA Corporation | 234.3 Million USD | -430.731% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -433.264% |
| Bionomics Limited | 27.64 Million USD | -4397.46% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -209.789% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -1057.957% |
| uniQure N.V. | 831.68 Million USD | -49.516% |
| Cassava Sciences, Inc. | 151.66 Million USD | -719.915% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -27817.697% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -354.025% |
| Forte Biosciences, Inc. | 38.98 Million USD | -3090.115% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -30429.639% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -3276.251% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -17113.552% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -35297.296% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -10419.474% |
| Altimmune, Inc. | 210.64 Million USD | -490.347% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -59.858% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -1057.957% |
| Compugen Ltd. | 121.33 Million USD | -924.863% |
| Peak Bio, Inc. | 2.59 Million USD | -47793.23% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -621.597% |
| Benitec Biopharma Inc. | 52.21 Million USD | -2281.741% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -263.749% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -3476.071% |
| Zura Bio Limited | 100.84 Million USD | -1133.112% |
| PolyPid Ltd. | 15.37 Million USD | -7989.429% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -942.458% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -3476.071% |
| Instil Bio, Inc. | 325.63 Million USD | -281.877% |
| argenx SE | 4.54 Billion USD | 72.625% |
| Immunome, Inc. | 148.54 Million USD | -737.153% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -692.674% |
| Verona Pharma plc | 308.12 Million USD | -303.574% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -1329.992% |
| Shattuck Labs, Inc. | 159.56 Million USD | -679.316% |
| CervoMed Inc. | 9.97 Million USD | -12369.334% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -559.839% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -10819.45% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -593.128% |
| Moolec Science SA | 24.05 Million USD | -5070.23% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -20227.112% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -619.021% |
| AnaptysBio, Inc. | 452.38 Million USD | -174.876% |
| Design Therapeutics, Inc. | 289.64 Million USD | -329.324% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -1607.528% |
| NeurAxis, Inc. | 509.49 Thousand USD | -243965.139% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -22851.403% |
| Lumos Pharma, Inc. | 40.63 Million USD | -2959.961% |
| Achilles Therapeutics plc | 161.45 Million USD | -670.183% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -1329.992% |
| 180 Life Sciences Corp. | 5.25 Million USD | -23543.173% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -1665.648% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -14425.916% |
| Nutriband Inc. | 7.51 Million USD | -16442.258% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -388.251% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -523.934% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -1531.642% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -2047.087% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -136.166% |
| Palisade Bio, Inc. | 14.05 Million USD | -8749.324% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -491.316% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 14.812% |
| Neurogene Inc. | 222.57 Million USD | -458.696% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -92.308% |
| AEON Biopharma, Inc. | 6.84 Million USD | -18066.647% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -174.483% |
| Sesen Bio, Inc. | 189.17 Million USD | -557.335% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -357.395% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -8968.836% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -59.352% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -365.743% |
| Athira Pharma, Inc. | 160.24 Million USD | -676.004% |
| Vaccinex, Inc. | 3.63 Million USD | -34146.957% |
| HCW Biologics Inc. | 28.51 Million USD | -4261.092% |
| XOMA Corporation | 234.3 Million USD | -430.731% |
| Nektar Therapeutics | 398.03 Million USD | -212.413% |
| Arvinas, Inc. | 1.3 Billion USD | 4.683% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -7198.719% |
| Merus N.V. | 458.49 Million USD | -171.216% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -508.471% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -590.055% |
| Rezolute, Inc. | 132.73 Million USD | -836.82% |
| Clene Inc. | 52.34 Million USD | -2275.78% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -8232.332% |
| BeyondSpring Inc. | 24.8 Million USD | -4912.524% |
| Synlogic, Inc. | 75.55 Million USD | -1545.939% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -10383.114% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -13179.656% |
| Peak Bio, Inc. | 2.59 Million USD | -47793.23% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -611.254% |
| Krystal Biotech, Inc. | 818.35 Million USD | -51.952% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -417.184% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -71.332% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -34662.273% |
| MannKind Corporation | 475.19 Million USD | -161.682% |
| Ikena Oncology, Inc. | 192.09 Million USD | -547.35% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -9197.944% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -967.031% |
| Gossamer Bio, Inc. | 311.91 Million USD | -298.667% |
| CohBar, Inc. | 16.36 Million USD | -7498.267% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -3436.408% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -16899.412% |
| Legend Biotech Corporation | 1.84 Billion USD | 32.733% |
| Mural Oncology plc | 301.74 Million USD | -312.105% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -3883.684% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -21791.168% |
| Disc Medicine, Inc. | 367.99 Million USD | -237.913% |
| Champions Oncology, Inc. | 26.13 Million USD | -4658.56% |
| REGENXBIO Inc. | 573.97 Million USD | -116.65% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -45818.315% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -705.453% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -10197.7% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -265.7% |
| Vaxart, Inc. | 91.83 Million USD | -1254.14% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -1975.837% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -738.356% |
| Cellectis S.A. | 334.27 Million USD | -272.007% |
| Longeveron Inc. | 12.17 Million USD | -10111.094% |
| Repare Therapeutics Inc. | 253.9 Million USD | -389.761% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 61.909% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -519.131% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 40.462% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -76423.508% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -347.77% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -662.429% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -796.26% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -4772.294% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 94.529% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -7.764% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -10082.157% |
| Veru Inc. | 50.59 Million USD | -2357.722% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -2629.803% |
| Cingulate Inc. | 3.49 Million USD | -35515.918% |
| Passage Bio, Inc. | 150.54 Million USD | -726.004% |
| Context Therapeutics Inc. | 16.06 Million USD | -7641.565% |
| Exicure, Inc. | 11.58 Million USD | -10638.402% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -230.678% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -669.297% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -7017.142% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -273.712% |
| Nuvalent, Inc. | 732.38 Million USD | -69.789% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -8221.068% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -1288.556% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -8662.645% |
| OmniAb, Inc. | 401.98 Million USD | -209.342% |
| Anew Medical, Inc. | 19.45 Million USD | -6291.396% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -4552.702% |
| Lipocine Inc. | 23 Million USD | -5306.3% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -789.445% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -306.953% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -1381.402% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -923.126% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -15571.166% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -40.943% |
| Ocugen, Inc. | 64.54 Million USD | -1826.514% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -898.472% |
| Q32 Bio Inc. | 306.11 Million USD | -306.217% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -29451.022% |
| Alumis Inc. Common Stock | 89.61 Million USD | -1287.657% |
| Equillium, Inc. | 50.53 Million USD | -2360.928% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -1553.71% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -2912.844% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -73010.786% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -4656.922% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -1829.683% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -33263.813% |
| Dominari Holdings Inc. | 57.55 Million USD | -2060.442% |
| Edesa Biotech, Inc. | 8.89 Million USD | -13887.018% |
| vTv Therapeutics Inc. | 11.01 Million USD | -11186.141% |
| Bio-Techne Corporation | 2.81 Billion USD | 55.797% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -32.695% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -53.245% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -347.844% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -2881.888% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -86.269% |
| Nkarta, Inc. | 378.88 Million USD | -228.202% |
| BioCardia, Inc. | 2.98 Million USD | -41530.633% |
| Iterum Therapeutics plc | 26.25 Million USD | -4635.546% |